Cintas (CTAS) Return on Sales (2009 - 2026)

Cintas (CTAS) posted Return on Sales of 0.0% for Q2 2026, down 0.54% sequentially from 0.0% in Q1 2026, and little changed YoY from 0.0% in Q2 2025.

Cintas (CTAS) Return on Sales (2009 - 2026) Analysis & Trends

Cintas has reported Return on Sales for 18 years, with the latest figure at 0.0% in Q2 2026.

Quarterly Return on Sales changed 0.0% year-over-year to 0.0% in Q2 2026, while the trailing twelve-month figure through May 2026 was 0.0% (changed 0.0% YoY) and the FY2026 annual result came in at 0.0%, changed 0.0% from the prior year.
Return on Sales retreated to 0.0% in Q2 2026 per CTAS's latest filing, from 0.0% in the prior quarter.
Over five years, Return on Sales peaked at 0.0% in Q3 2024 and troughed at 0.0% in Q2 2022.
A 5-year average of 0.0% and a median of 0.0% in 2024 frame the typical range for Return on Sales.
The widest YoY moves for Return on Sales: up 0 bps in 2022, down 0 bps in 2022.
Over 5 years, Return on Sales stood at 0.0% in 2022, then increased by 6 bps to 0.0% in 2023, then rose by 11 bps to 0.0% in 2024, then rose by 1 bps to 0.0% in 2025, then decreased by 1 bps to 0.0% in 2026.
According to Business Quant data, Return on Sales over the past three periods registered 0.0%, 0.0%, and 0.0% for Q2 2026, Q1 2026, and Q4 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROS (Qtr)
1	Cintas	81.75 Bn	81.46 Bn	1.48 Bn	0.00%
2	Relx	65.77 Bn	65.60 Bn	-	-
3	Copart	31.81 Bn	28.46 Bn	732.88 Mn	0.00%
4	Global Payments	25.23 Bn	19.82 Bn	2.03 Bn	0.00%
5	Rb Global	16.08 Bn	15.56 Bn	935.50 Mn	0.00%
6	Aramark	15.67 Bn	15.17 Bn	430.34 Mn	0.00%
7	UL Solutions	15.17 Bn	14.73 Bn	417.00 Mn	0.00%
8	Rentokil Initial	11.92 Bn	9.39 Bn	-	-
9	Dolby Laboratories	6.10 Bn	5.43 Bn	264.68 Mn	0.00%
10	Unifirst	5.25 Bn	5.08 Bn	234.73 Mn	0.00%

Download Data